Want to see HK:6990 full AI Analyst Report?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) AI Stock Analysis
Top Page
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
(HKEX:6990)
The score is primarily supported by improving financial performance (TTM rebound to profitability, strong cash flow improvement, and a low-leverage balance sheet). This is offset by very weak valuation (P/E 762.1) and only neutral-to-soft technicals (negative MACD and price below the 50-day average), keeping the overall score in the mid range.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 101.54B
- Dividend Yield
- ―
- Average Volume (3M)
- 653.39K
- Price to Earnings (P/E)
- 653.4
- Beta (1Y)
- 0.64
- Revenue Growth
- 43.88%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 2,300
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the Peopl...
How the Company Makes Money
The company makes money primarily through (1) commercialization of its approved products (if applicable at the time of reporting) by selling biopharmaceuticals to hospitals, pharmacies, distributors and/or other healthcare channels, generating produc...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Financials show a meaningful TTM inflection: revenue up ~64%, a return to positive net income, and positive operating/free cash flow. The balance sheet is a major strength with very low leverage (TTM debt-to-equity ~0.02) and improved equity capitalization. However, operating profitability is not yet fully proven (EBIT margin still slightly negative; EBITDA margin thin) and prior years showed recurring losses and cash burn, raising durability risk.
Income Statement
62PositiveBalance Sheet
78PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.20B | 2.06B | 1.93B | 1.54B | 803.93M | 31.79M |
| Gross Profit | 1.64B | 1.48B | 1.27B | 759.18M | 527.11M | -10.93M |
| EBITDA | 81.93M | -249.23M | -47.36M | -308.31M | -351.19M | -775.80M |
| Net Income | 126.87M | -381.97M | -266.77M | -574.13M | -616.10M | -875.26M |
Balance Sheet | ||||||
| Total Assets | 6.32B | 5.99B | 4.27B | 3.51B | 993.14M | 996.97M |
| Cash, Cash Equivalents and Short-Term Investments | 4.77B | 4.56B | 3.08B | 2.53B | 117.54M | 100.31M |
| Total Debt | 81.35M | 88.44M | 126.75M | 59.92M | 3.01B | 2.93B |
| Total Liabilities | 984.87M | 1.12B | 959.34M | 1.18B | 4.22B | 4.24B |
| Stockholders Equity | 5.34B | 4.87B | 3.31B | 2.33B | -3.21B | -3.24B |
Cash Flow | ||||||
| Free Cash Flow | 431.95M | -306.55M | -510.89M | -22.69M | -309.84M | -609.73M |
| Operating Cash Flow | 551.52M | -180.30M | -429.77M | 59.56M | -270.85M | -517.18M |
| Investing Cash Flow | -736.44M | 411.01M | -822.00M | -1.03B | -32.15M | -92.84M |
| Financing Cash Flow | -64.89M | 1.73B | 1.04B | 2.38B | 313.45M | 675.92M |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6990, the sentiment is Negative. The current price of 424.80 is below the 20-day moving average (MA) of 454.27, below the 50-day MA of 475.44, and below the 200-day MA of 458.00, indicating a bearish trend. The MACD of -9.21 indicates Positive momentum. The RSI at 39.42 is Neutral, neither overbought nor oversold. The STOCH value of 4.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6990.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Peers Comparison
Overall Rating
HK:180181Outperform
HK:226981Outperform
HK:269664.6Neutral- HK:699059Neutral
HK:992642Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1801 | 81Outperform | HKD 139.32B | 95.59 | 6.06% | ― | 42.64% | 9.67% |
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:6990 | 59Neutral | HKD 101.54B | 653.42 | 2.43% | ― | 43.88% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9926 | 42Neutral | HKD 76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6990 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H | 424.80 | -26.40 | -5.85% | |
| HK:1801 | Innovent Biologics | 79.75 | -10.45 | -11.59% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:9926 | Akeso, Inc. | 81.50 | -36.80 | -31.11% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Corporate Events
Kelun-Biotech Seeks New Lung Cancer Indication for Core ADC sac-TMT After Strong Phase 3 Data
Sichuan Kelun-Biotech Biopharmaceutical announced that China’s National Medical Products Administration has accepted a new indication application for its core TROP2-directed ADC sacituzumab tirumotecan. The filing seeks approval for sac-TMT in...
Kelun-Biotech’s ADC Combo Shows Breakthrough Benefit in First-Line Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical, a Chinese oncology-focused drug developer, specializes in innovative antibody-drug conjugates that target solid tumors such as non-small cell lung cancer. Its lead assets include the TROP2-directed ADC sacituz...
Kelun-Biotech Advances Ultra-Long-Acting Asthma Antibody Into Phase 3 After Positive Data
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a China-based biopharma focused on innovative biologics, is co-developing SKB378/WIN378, an ultra-long-acting monoclonal antibody against TSLP for asthma, together with Windward Bio and Harbour BioMe...
Kelun-Biotech Swings to Profit as Core Cancer Drug sac-TMT Gains Ground
Sichuan Kelun-Biotech reported interim 2026 results showing revenue of RMB978.3 million, up 2.9% year on year, and a sharp swing to a profit of RMB388.0 million from a loss a year earlier, supported by an 11.7% rise in gross profit and stronger cash...
Kelun-Biotech Sets August Board Meeting and Global Webcast for 2026 Interim Results
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has scheduled a board meeting for 17 August 2026 to review and approve its interim results for the six months ended 30 June 2026, alongside other corporate matters. The timing underscores the company&...
Kelun-Biotech Boosts Bank of China Structured Deposits to RMB1.1 Billion
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has entered into a third structured deposit agreement with Bank of China, subscribing to a principal-guaranteed product with a floating return valued at RMB400 million. Following this latest subscript...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 23, 2026